4.7 Review

Targeting XIAP for the treatment of malignancy

Journal

CELL DEATH AND DIFFERENTIATION
Volume 13, Issue 2, Pages 179-188

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/sj.cdd.4401826

Keywords

XIAP; drug discovery; small molecules; antisense; apoptosis

Ask authors/readers for more resources

X-linked inhibitor of apoptosis protein ( XIAP) is a member of the inhibitor of apoptosis proteins family of caspase inhibitors that selectively binds and inhibits caspases-3, -7 and -9, but not caspase-8. As such, XIAP blocks a substantial portion of the apoptosis pathway and is an attractive target for novel therapeutic agents for the treatment of malignancy. Antisense oligonucleotides directed against XIAP are effective in vitro and are currently being evaluated in clinical trials. Small molecule XIAP inhibitors that target the baculovirus IAP repeat (BIR) 2 or BIR 3 domain are in preclinical development and are advancing toward the clinic. This review will discuss the progress being made in developing antisense and small-molecule XIAP inhibitors.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available